NCT02367027 - Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

June 30, 2015

Conditions

Pharmacokinetics

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Single dose of 10 mg oral suspension (dry powder) in fasted conditions.

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Single dose of 20 mg oral suspension (dry powder) in fed conditions.

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Single dose of 10 mg oral suspension in fasted conditions.

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Single dose of 10 mg tablet in fasted conditions.

Trial Locations (1)

Mannheim